Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Aug 2022
Stelara (ustekinumab) approved by the U.S. FDA to treat paediatric patients with active psoriatic arthritis
1 August 2022 - As the first and only biologic targeting both cytokines interleukin-12 and interleukin-23, Stelara provides a new therapeutic ...
Posted by Michael Wonder on 01 Aug 2022
ALX Oncology’s evorpacept receives fast track designation from FDA as first-line treatment for head and neck squamous cell carcinoma
1 August 2022 - ALX Oncology today announced that the U.S. FDA has granted fast track designation to evorpacept, a next ...
Posted by Michael Wonder on 01 Aug 2022
Changes to cost recovery arrangements from 1 August 2022
1 August 2022 - PBS cost recovery fees and charges have now been updated with the fees that will apply ...
Posted by Michael Wonder on 01 Aug 2022
HSE weighs up impact of obesity drug that costs 250 Euros a month
31 July 2022 - Health authorities are evaluating whether a game changing new obesity drug should be used in Ireland ...
Posted by Michael Wonder on 01 Aug 2022
Gamida Cell announces FDA acceptance of biologics license application for omidubicel with priority review
1 August 2022 - PDUFA target action date is 30 January 2023. ...
Posted by Michael Wonder on 01 Aug 2022
Changes to PBS listing of hydromorphone oral solution
1 August 2022 - Changes to the PBS listing of hydromorphone hydrochloride 1 mg/mL oral solution (473 mL) are being ...
Posted by Michael Wonder on 01 Aug 2022
Mum fears dance loving toddler will lose ability to walk without unfunded drug
1 August 2022 - An Auckland toddler who loves to dance may soon be unable to walk or stand if ...
Posted by Michael Wonder on 01 Aug 2022
PBS listings will help people with spinal muscular atrophy, schizophrenia and multiple sclerosis
1 August 2022 - From today, Australians will have access to new and updated PBS listings, including a new spinal ...
Posted by Michael Wonder on 01 Aug 2022
TGA approves new medicine for NSCLC patients with an EGFR exon 20 mutation
1 August 2020 - First medicine approved by the TGA for this mutation. ...
Posted by Michael Wonder on 31 Jul 2022
FDA provides update on agency response to monkeypox outbreak
29 July 2022 - Today, the U.S. FDA is providing an update on its multi-pronged response to monkeypox in the United ...
Posted by Michael Wonder on 31 Jul 2022
U.S. would gain power to negotiate drug prices under Manchin-Schumer Bill
31 July 2022 - Legislation would also cap out of pocket drug costs for Medicare beneficiaries at $2,000 a year. ...
Posted by Michael Wonder on 31 Jul 2022
Schedule of Pharmaceutical Benefits - 1 August 2022
1 August 2022 - The August 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jul 2022
2022 October price disclosure cycle – patient savings
29 July 2022 - Indicative brand price reductions and patient savings resulting from the 2022 October Cycle of Price Disclosure have ...
Posted by Michael Wonder on 31 Jul 2022
Gilead Sciences statement on FDA acceptance of new drug application for investigational lenacapavir
27 July 2022 - Gilead Sciences today announced that the U.S. FDA accepted for review the new drug application resubmission for ...
Posted by Michael Wonder on 31 Jul 2022
New Zealand Pharmaceutical Schedule - 1 August 2022
1 August 2022 - The August 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...